Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.
Erica L. Mayer, MD, MPH
Advertisement
Articles by Erica L. Mayer, MD, MPH
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
The expert explained her research focused on the role of CDK4/6 inhibitors in treating breast cancer.
Advertisement
Latest Updated Articles
7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 InhibitorPublished: April 18th 2022 | Updated:
Oral SERD Regimen May Prolong Efficacy in Second-Line Breast Cancer CarePublished: October 21st 2025 | Updated:
What Were the Key Presentations at ESMO 2025? Oncology Experts DiscussPublished: October 27th 2025 | Updated:
Erica L. Mayer, MD, MPH, Discusses New Targeted Therapies in Breast Cancer TreatmentPublished: December 23rd 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
3
Daratumumab Approval May Be “Game Changer” in High-Risk Smoldering Myeloma
4
What Do Physicians and Patients Think About ADCs as Cancer Treatment?
5
